The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has ...
The First International Symposium on Pheochromocytoma, held in October 2005, included discussions about developments concerning these rare catecholamine-producing tumors. Recommendations were made ...
Researchers have developed two simple, easy-to-deliver sessions to improve the wellbeing of staff in pediatric critical care (PCC) units in UK hospitals.
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025. The FDA granted priority review to a supplemental new ...
More than 13,000 women are diagnosed with the cancer each year, but those rates are dropping thanks to advances in ...
A clinical social worker describes how the application of positive psychology interventions may improve well-being and ...